The biotechnology industry has seen an unparalleled boom following the COVID-19 disease, with companies such as Moderna spearheading this charge.
Moderna has become a household name in the world, known primarily for its quick development and deployment of mRNA-1273 COVID- 19 vaccine as an embodiment of hope and scientific revolution.
However, as the acute phase of the pandemic wanes, the question arises: What is the future for Moderna in a world beyond COVID-19?
Read More: This Biotech Company Could be a Hidden Gem
Moderna Biotech Company – Project Portfolio
Moderna is constantly broadening its research and development beyond the COVID-19 vaccine, exploring various other projects that utilize their groundbreaking mRNA technology.
As per conversations with the CEO of Moderna, Stéphane Bancel, it has been possible for this company to quickly adapt its mRNA platform in response to COVID-19 pandemic showing that such a platform is flexible and rapid enough at developing vaccines which are effective.
This flexibility has now been directed towards the creation of vaccines for other infectious diseases such as RSV (respiratory syncytial virus), HIV, Zika and Epstein-Barr Virus thus demonstrating that mRNA technology can address a wide range of health concerns.
Moreover, the fate of mRNA vaccines seems to be bright since there are high expectations for a flu vaccine capable of providing universal protection against various strains.
The flu vaccine of the company, mRNA-1010 has demonstrated promising data in phase 3 trials and it is predicted that this product will be more efficient than currently available on market vaccines.
On the other hand, the mRNA-1345 RSV vaccine from Moderna is moving quickly through clinical trials. This shift into other vaccine segments shows that Moderna is looking to use its mRNA technology platform in treating a wider range of infectious diseases.
Opportunities and Challenges
The Moderna biotech company is at a crossroads following the Covid-19 pandemic and an influx of potential as well as challenges.
The unprecedented success of its COVID-19 vaccine did not only enable the company to have a huge amount of finance but also gave it an international platform for future R&D.
First, the pipeline that is currently in place with Moderna is flooded by potential vaccines for influenza RSV and Zika as well as more ambitious projects to combat cancer or rare genetic disorders.
Looking ahead, the adaptability of mRNA technology places Moderna to perhaps transform virtually every health problem from preventative measures into curative solutions and entering an age that will be dominated by medicine.
The post-pandemic biotech industry journey for Moderna is characterized by a deliberate change in the route towards diversification and product pipeline management as well as manufacturing issues.
Moderna capitalizes on the remarkable success of their mRNA-1273 COVID -19 vaccine by using its technology platform for diseases beyond those caused by coronavirus such as cancer.
The company collaborates with Big Pharma, including Merck & Co., to create personalized cancer vaccines such as mRNA-4157 which are about to enter the third phase of clinical trials.
This cooperative process is meant to create creative cancer treatment modalities but not without challenges of manufacturing complexities as that seen in the CAR-T therapy space.
Highly customized medicine is prone to unforeseen complications in manufacturing, as specialized production is required for each patient’s tumor profile, increasing the probability of operational bottlenecks.
Scalability and Viability
Scaling of production and distribution for new products is one the focal points in Moderna’s future strategy. Logistically speaking, the company has shown its prowess in speeding up and distributing of COVID-19 vaccines all over the world.
Nevertheless, copying this triumph for a broader array of products is no easy task because it requires maneuvering through the challenging terrain that consists of strategic partnerships, manufacturing infrastructure and supply chains.
Moderna’s experience during the pandemic with executive decision making that had to be rapid and being able to adjust quickly enough for a global health crisis is what has prepared it for these challenges.
The decentralized nature of this company’s structure ensured flexibility and mobility, which is critical for scaling production.
Furthermore, the supply chain strategy that facilitated rapid deployment of COVID-19 vaccine entailed a huge scale up in production involving an intricate network for new and existing suppliers to provide raw materials, logistics resources and cooling units.
Such complex coordination was also observed in distribution hubs, emergency vaccination centers and hospitals.
Obviously, the change in priorities of the supply chain automatically affects other drugs manufacturing now, especially those that require similar raw materials or temperature-controlled storage.
Financially, the Moderna biotech company is facing a terrain that has reduced demand for COVID-19 vaccine with strategic investments and partnerships to drive growth in new therapeutic areas.
Although COVID-19 vaccine revenue saw a decline, with Q4 sales of $ 4.8 billion falling from the previous year’s number; Moderna is determined to reinvest in its core mRNA platform for diseases such as influenza and latent infection.
The company is also seeking external investment avenues and has already ventured into massive collaborations and acquisitions to strengthen its R&D capacities. This also involves collaborations with firms such as CytomX and
Personalis, its first M&A deal in which OriCiro was acquired for $85 million. These tactical moves reflect Moderna’s desire to go beyond the pandemic and explore more technological, therapeutic spaces which are not without their own set of challenges regarding manufacturing capacity and market demand.
Moderna has taken active measures to ensure that ethical and equitable distribution is maintained to address global health inequalities, especially during the COVID-19 pandemic.
First, Moderna committed to a nonenforcement of COVID-19 related patents during the pandemic period for wider vaccine production.
The company further pledged to provide up to 500 million doses for the COVAX Facility targeting lower-income countries and facilitated over 50 million through COVAX by September of last year.
A critical step towards the long-term healthcare solution in regions facing vaccine inequity is Moderna’s plans to establish an mRNA facility in Africa that will produce up to 500 million doses annually.
Additionally, the Moderna biotech company is increasing its capacity to provide 1 billion doses more in low-income countries for the year 2022.
However, despite these initiatives’ challenges remain with some shareholders and health experts calling for more aggressive actions to achieve global vaccine equity highlighting issues related to pricing as well allocation of doses in low-income countries.
This need to tackle these gaps is further accentuated by the fact that such variants as Omicron spread so easily, a clear sign of global interdependence in terms of health.
Moderna Biotech – A Success?
Moderna is leading a biotech revolution driven by the pandemic. Its future after the pandemic looks bright because of innovative technologies, steady pipeline and good financial standing.
However, the road forward is complex, requiring creative approaches and efficacious solutions that can be scaled-up with a commitment to global health equity.
This landscape will not only determine its own fate but also the future of biotechnology and healthcare.
You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Faith is an enthusiastic freelancer and regular contributor to numerous finance blogs, creating valuable pieces to educate individuals on finance and fintech options. As a skilled writer, Faith has created content for diverse industries—if it exists, she’s likely written about it!